Top

07-03-2016 | Pediatric leukemia | Article

Obesity and Metabolic Syndrome Among Adult Survivors of Childhood Leukemia

Journal: Current Treatment Options in Oncology

Authors: Todd M. Gibson, PhD, Matthew J. Ehrhardt, MD, MS, Kirsten K. Ness, PT, PhD

Abstract

Treatment-related obesity and the metabolic syndrome in adult survivors of childhood acute lymphoblastic leukemia (ALL) are risk factors for cardiovascular disease. Both conditions often begin during therapy. Preventive measures, including dietary counseling and tailored exercise, should be initiated early in the course of survivorship, with referral to specialists to optimize success. However, among adults who develop obesity or the metabolic syndrome and who do not respond to lifestyle therapy, medical intervention may be indicated to manage underlying pathology, such as growth hormone deficiency, or to mitigate risk factors of cardiovascular disease. Because no specific clinical trials have been done in this population to treat metabolic syndrome or its components, clinicians who follow adult survivors of childhood ALL should use the existing American Heart Association/National Heart Lung and Blood Institute Scientific Statement to guide their approach.

Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185–96. doi:10.1053/j.seminhematol.2013.06.007.CrossRefPubMedPubMedCentral

Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008;111(12):5515–23. doi:10.1182/blood-2007-10-117150.CrossRefPubMedPubMedCentral

Armstrong GT, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson MM, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014;32(12):1218–27. doi:10.1200/JCO.2013.51.1055.CrossRefPubMedPubMedCentral

4.•

Armstrong GT, Oeffinger KC, Chen Y, Kawashima T, Yasui Y, Leisenring W, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31(29):3673–80. doi:10.1200/JCO.2013.49.3205. This study documents the multiplicative risk of obesity, hypertension, dyslipidemia, and diabetes on cardiovascular disease among childhood cancer survivors exposed to known cardiotoxic treatment exposures.CrossRefPubMedPubMedCentral

5.•

Smith WA, Li C, Nottage KA, Mulrooney DA, Armstrong GT, Lanctot JQ, et al. Lifestyle and metabolic syndrome in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer. 2014;120(17):2742–50. doi:10.1002/cncr.28670. This paper describes the protective effects of a healthy lifestyle (diet, physical activity) on the development of metabolic syndrome among childhood cancer survivors, even in the presence of past cranial radiation exposure.CrossRefPubMedPubMedCentral

Cox CL, Nolan VG, Leisenring W, Yasui Y, Ogg SW, Mertens AC, et al. Noncancer-related mortality risks in adult survivors of pediatric malignancies: the childhood cancer survivor study. J Cancer Surviv. 2014;8(3):460–71. doi:10.1007/s11764-014-0353-7.CrossRefPubMedPubMedCentral

Rogers PC, Meacham LR, Oeffinger KC, Henry DW, Lange BJ. Obesity in pediatric oncology. Pediatr Blood Cancer. 2005;45(7):881–91. doi:10.1002/pbc.20451.CrossRefPubMed

Oeffinger KC, Mertens AC, Sklar CA, Yasui Y, Fears T, Stovall M, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2003;21(7):1359–65.CrossRefPubMed

Garmey EG, Liu Q, Sklar CA, Meacham LR, Mertens AC, Stovall MA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2008;26(28):4639–45. doi:10.1200/JCO.2008.16.3527.CrossRefPubMedPubMedCentral

10.

van der Does-van den Berg A, de Vaan GA, van Weerden JF, Hahlen K, van Weel-Sipman M, Veerman AJ. Late effects among long-term survivors of childhood acute leukemia in The Netherlands: a Dutch Childhood Leukemia Study Group Report. Pediatr Res. 1995;38(5):802–7. doi:10.1203/00006450-199511000-00027.CrossRef

11.

Oeffinger KC, Buchanan GR, Eshelman DA, Denke MA, Andrews TC, Germak JA, et al. Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2001;23(7):424–30.CrossRefPubMed

12.•

Wilson CL, Liu W, Yang JJ, Kang G, Ojha RP, Neale GA, et al. Genetic and clinical factors associated with obesity among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort. Cancer. 2015. doi:10.1002/cncr.29153. This manuscript provides preliminary information on the potential genetic risk factors for radiation-induced damage to the hypothalamic-pituitary axis.

13.

Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14. doi:10.1001/jama.2014.732.CrossRefPubMedPubMedCentral

14.

Jarfelt M, Lannering B, Bosaeus I, Johannsson G, Bjarnason R. Body composition in young adult survivors of childhood acute lymphoblastic leukaemia. Eur J Endocrinol. 2005;153(1):81–9. doi:10.1530/eje.1.01931.CrossRefPubMed

15.•

Karlage RE, Wilson CL, Zhang N, Kaste S, Green DM, Armstrong GT, et al. Validity of anthropometric measurements for characterizing obesity among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study. Cancer. 2015;121(12):2036–43. doi:10.1002/cncr.29300. This analysis indicates that body mass index may not be the best measure of excess adiposity in childhood cancer survivors.CrossRefPubMed

16.

Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301–13. doi:10.1161/CIRCULATIONAHA.111.067264.CrossRefPubMed

17.

Ness KK, Baker KS, Dengel DR, Youngren N, Sibley S, Mertens AC, et al. Body composition, muscle strength deficits and mobility limitations in adult survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2007;49(7):975–81. doi:10.1002/pbc.21091.CrossRefPubMed

18.••

Ness KK, DeLany JP, Kaste SC, Mulrooney DA, Pui CH, Chemaitilly W, et al. Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia. Blood. 2015;125(22):3411–9. doi:10.1182/blood-2015-01-621680. This manuscript describes energy balance and fitness in long term survivors of childhood ALL, demonstrating that survivors treated without CRT are still at risk for impairments that may interfere with their ability to adopt a lifestyle that includes regular physical activity.CrossRefPubMedPubMedCentral

19.

Chemaitilly W, Li Z, Huang S, Ness KK, Clark KL, Green DM, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol. 2015;33(5):492–500. doi:10.1200/JCO.2014.56.7933.CrossRefPubMedPubMedCentral

20.

Link K, Moell C, Garwicz S, Cavallin-Stahl E, Bjork J, Thilen U, et al. Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab. 2004;89(10):5003–12. doi:10.1210/jc.2004-0126.CrossRefPubMed

21.

Karaman S, Ercan O, Yildiz I, Bolayirli M, Celkan T, Apak H, et al. Late effects of childhood ALL treatment on body mass index and serum leptin levels. J Pediatr Endocrinol Metab. 2010;23(7):669–74.CrossRefPubMed

22.

Skoczen S, Tomasik PJ, Bik-Multanowski M, Surmiak M, Balwierz W, Pietrzyk JJ, et al. Plasma levels of leptin and soluble leptin receptor and polymorphisms of leptin gene-18G > A and leptin receptor genes K109R and Q223R, in survivors of childhood acute lymphoblastic leukemia. J Exp Clin Cancer Res. 2011;30:64. doi:10.1186/1756-9966-30-64.CrossRefPubMedPubMedCentral

23.

Tonorezos ES, Vega GL, Sklar CA, Chou JF, Moskowitz CS, Mo Q, et al. Adipokines, body fatness, and insulin resistance among survivors of childhood leukemia. Pediatr Blood Cancer. 2012;58(1):31–6. doi:10.1002/pbc.22964.CrossRefPubMedPubMedCentral

24.

Janiszewski PM, Oeffinger KC, Church TS, Dunn AL, Eshelman DA, Victor RG, et al. Abdominal obesity, liver fat, and muscle composition in survivors of childhood acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2007;92(10):3816–21. doi:10.1210/jc.2006-2178.CrossRefPubMed

25.

Reilly JJ, Brougham M, Montgomery C, Richardson F, Kelly A, Gibson BE. Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2001;86(8):3742–5. doi:10.1210/jcem.86.8.7764.CrossRefPubMed

26.•

Chow EJ, Pihoker C, Friedman DL, Lee SJ, McCune JS, Wharton C, et al. Glucocorticoids and insulin resistance in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013;60(4):621–6. doi:10.1002/pbc.24364. These authors describe an association between glucocorticoid exposure and insulin resistance in children with ALL.CrossRefPubMedPubMedCentral

27.•

Yeshayahu Y, Koltin D, Hamilton J, Nathan PC, Urbach S. Medication-induced diabetes during induction treatment for ALL, an early marker for future metabolic risk? Pediatr Diabetes. 2015;16(2):104–8. doi:10.1111/pedi.12138. These authors describe an increased risk for later metabolic syndrome among children who develop medication induced diabetes during ALL therapy.CrossRefPubMed

28.

Davies JH, Evans BA, Jones E, Evans WD, Jenney ME, Gregory JW. Osteopenia, excess adiposity and hyperleptinaemia during 2 years of treatment for childhood acute lymphoblastic leukaemia without cranial irradiation. Clin Endocrinol (Oxf). 2004;60(3):358–65.CrossRef

29.

Zareifar S, Shorafa S, Haghpanah S, Karamizadeh Z, Adelian R. Association of serum leptin level with obesity in children with acute lymphoblastic leukemia. Iran J Ped Hematol Oncol. 2015;5(3):116–24.PubMedPubMedCentral

30.

Jansen H, Postma A, Stolk RP, Kamps WA. Acute lymphoblastic leukemia and obesity: increased energy intake or decreased physical activity? Support Care Cancer. 2009;17(1):103–6. doi:10.1007/s00520-008-0531-0.CrossRefPubMed

31.

Tan SY, Poh BK, Chong HX, Ismail MN, Rahman J, Zarina AL, et al. Physical activity of pediatric patients with acute leukemia undergoing induction or consolidation chemotherapy. Leuk Res. 2013;37(1):14–20. doi:10.1016/j.leukres.2012.09.005.CrossRefPubMed

32.

Ross JA, Oeffinger KC, Davies SM, Mertens AC, Langer EK, Kiffmeyer WR, et al. Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2004;22(17):3558–62. doi:10.1200/JCO.2004.11.152.CrossRefPubMed

33.

Brennan BM, Rahim A, Blum WF, Adams JA, Eden OB, Shalet SM. Hyperleptinaemia in young adults following cranial irradiation in childhood: growth hormone deficiency or leptin insensitivity? Clin Endocrinol (Oxf). 1999;50(2):163–9.CrossRef

34.

Szymon S, Bik-Multanowski M, Balwierz W, Pietrzyk JJ, Surmiak M, Strojny W, et al. Homozygosity for the rs9939609T allele of the FTO gene may have protective effect on becoming overweight in survivors of childhood acute lymphoblastic leukaemia. J Genet. 2011;90(2):365–8.CrossRefPubMed

35.

Hinney A, Nguyen TT, Scherag A, Friedel S, Bronner G, Muller TD, et al. Genome wide association (GWA) study for early onset extreme obesity supports the role of fat mass and obesity associated gene (FTO) variants. PLoS One. 2007;2(12):e1361. doi:10.1371/journal.pone.0001361.CrossRefPubMedPubMedCentral

36.

Hubacek JA, Bohuslavova R, Kuthanova L, Kubinova R, Peasey A, Pikhart H, et al. The FTO gene and obesity in a large Eastern European population sample: the HAPIEE study. Obesity (Silver Spring). 2008;16(12):2764–6. doi:10.1038/oby.2008.421.CrossRef

37.

Breene RA, Williams RM, Hartle J, Gattens M, Acerini CL, Murray MJ. Auxological changes in UK survivors of childhood acute lymphoblastic leukaemia treated without cranial irradiation. Br J Cancer. 2011;104(5):746–9. doi:10.1038/bjc.2011.16.CrossRefPubMedPubMedCentral

38.

Chow EJ, Pihoker C, Hunt K, Wilkinson K, Friedman DL. Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer. 2007;110(10):2313–20. doi:10.1002/cncr.23050.CrossRefPubMed

39.

Zhang FF, Rodday AM, Kelly MJ, Must A, MacPherson C, Roberts SB, et al. Predictors of being overweight or obese in survivors of pediatric acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer. 2014;61(7):1263–9. doi:10.1002/pbc.24960.CrossRefPubMedPubMedCentral

40.

Esbenshade AJ, Simmons JH, Koyama T, Lindell RB, Friedman DL. Obesity and insulin resistance in pediatric acute lymphoblastic leukemia worsens during maintenance therapy. Pediatr Blood Cancer. 2013;60(8):1287–91. doi:10.1002/pbc.24489.CrossRefPubMed

41.

Winkler MR, Hockenberry MJ, McCarthy KS, Silva SG. Trajectories of obesity and overweight rates among survivors of childhood acute lymphoblastic leukemia. Oncol Nurs Forum. 2015;42(4):E287–93. doi:10.1188/15.ONF.E287-E293.CrossRefPubMed

42.•

Nottage KA, Ness KK, Li C, Srivastava D, Robison LL, Hudson MM. Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia—from the St. Jude Lifetime Cohort. Br J Haematol. 2014;165(3):364–74. doi:10.1111/bjh.12754. This manuscript provides an estimate of the prevalence of metabolic syndrome using data from a large cohort of adult survivors of childhood ALL.CrossRefPubMedPubMedCentral

43.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112(17):2735–52. doi:10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed

44.

Geenen MM, Bakker PJ, Kremer LC, Kastelein JJ, van Leeuwen FE. Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy. Pediatr Blood Cancer. 2010;55(4):690–7. doi:10.1002/pbc.22518.CrossRefPubMed

45.

Meacham LR, Chow EJ, Ness KK, Kamdar KY, Chen Y, Yasui Y, et al. Cardiovascular risk factors in adult survivors of pediatric cancer—a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2010;19(1):170–81. doi:10.1158/1055-9965.EPI-09-0555.CrossRefPubMedPubMedCentral

46.

Gurney JG, Ness KK, Sibley SD, O’Leary M, Dengel DR, Lee JM, et al. Metabolic syndrome and growth hormone deficiency in adult survivors of childhood acute lymphoblastic leukemia. Cancer. 2006;107(6):1303–12. doi:10.1002/cncr.22120.CrossRefPubMed

47.

Oudin C, Simeoni MC, Sirvent N, Contet A, Begu-Le Coroller A, Bordigoni P, et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood. 2011;117(17):4442–8. doi:10.1182/blood-2010-09-304899.CrossRefPubMed

48.

Talvensaari KK, Lanning M, Tapanainen P, Knip M. Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome. J Clin Endocrinol Metab. 1996;81(8):3051–5. doi:10.1210/jcem.81.8.8768873.PubMed

49.

van Waas M, Neggers SJ, Pieters R, van den Heuvel-Eibrink MM. Components of the metabolic syndrome in 500 adult long-term survivors of childhood cancer. Ann Oncol. 2010;21(5):1121–6. doi:10.1093/annonc/mdp414.CrossRefPubMed

50.

Esbenshade AJ, Simmons JH, Koyama T, Koehler E, Whitlock JA, Friedman DL. Body mass index and blood pressure changes over the course of treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011;56(3):372–8. doi:10.1002/pbc.22782.CrossRefPubMedPubMedCentral

51.

Kojima C, Kubota M, Nagai A, Adachi S, Watanabe K, Nakahata T. Adipocytokines in childhood cancer survivors and correlation with metabolic syndrome components. Pediatr Int. 2013;55(4):438–42. doi:10.1111/ped.12087.CrossRefPubMed

52.

Siviero-Miachon AA, Spinola-Castro AM, de Martino Lee ML, de Castro Monteiro CM, de Camargo Carvalho AC, Calixto AR, et al. Subcutaneous adipose tissue plays a beneficial effect on subclinical atherosclerosis in young survivors of acute lymphocytic leukemia. Vasc Health Risk Manag. 2015;11:479–88. doi:10.2147/VHRM.S86883.CrossRefPubMedPubMedCentral

53.

Mulrooney DA, Armstrong GT, Huang S, Ness KK, Ehrhardt MJ, Joshi VM, et al. Cardiac outcomes in adult survivors of childhood cancer exposed to cardiotoxic therapy: a cross-sectional study. Ann Intern Med. 2016;164(2):93–101. doi:10.7326/M15-0424.CrossRefPubMed

54.

Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606. doi:10.1136/bmj.b4606.CrossRefPubMedPubMedCentral

55.

Ness KK, Leisenring WM, Huang S, Hudson MM, Gurney JG, Whelan K, et al. Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer. 2009;115(9):1984–94. doi:10.1002/cncr.24209.CrossRefPubMedPubMedCentral

56.

Robien K, Ness KK, Klesges LM, Baker KS, Gurney JG. Poor adherence to dietary guidelines among adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008;30(11):815–22. doi:10.1097/MPH.0b013e31817e4ad9.CrossRefPubMedPubMedCentral

57.

World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC. 2007.

58.••

Follin C, Thilen U, Ahren B, Erfurth EM. Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. J Clin Endocrinol Metab. 2006;91(5):1872–5. doi:10.1210/jc.2005-2298. This non-randomized study reports the potential positive benefits of growth hormone replacement on components of the metabolic syndrome in ALL survivors.CrossRefPubMed

59.

Yuen KC, Heaney AP, Popovic V. Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician. Endocrine. 2016. doi:10.1007/s12020-015-0840-2.PubMed

60.

Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87(7):3136–41. doi:10.1210/jcem.87.7.8606.CrossRefPubMed

61.

Woodmansee WW, Zimmermann AG, Child CJ, Rong Q, Erfurth EM, Beck-Peccoz P, et al. Incidence of second neoplasm in childhood cancer survivors treated with GH: an analysis of GeNeSIS and HypoCCS. Eur J Endocrinol. 2013;168(4):565–73. doi:10.1530/EJE-12-0967.CrossRefPubMed

62.

Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91(9):3494–8. doi:10.1210/jc.2006-0656.CrossRefPubMed

63.•

Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A, et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J Clin Endocrinol Metab. 2014;99(6):2030–7. doi:10.1210/jc.2013-4159. These data indicate that growth hormone replacement does not increase risk of secondary central nervous syndrome neoplasms among childhood cancer survivors.CrossRefPubMedPubMedCentral

64.

Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128(17):1927–95. doi:10.1161/CIR.0b013e3182a88099.CrossRefPubMed

65.

Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50–103. doi:10.1016/j.jacc.2010.09.001.CrossRefPubMed

66.

Kourti M, Tragiannidis A, Makedou A, Papageorgiou T, Rousso I, Athanassiadou F. Metabolic syndrome in children and adolescents with acute lymphoblastic leukemia after the completion of chemotherapy. J Pediatr Hematol Oncol. 2005;27(9):499–501.CrossRefPubMed

67.

Trimis G, Moschovi M, Papassotiriou I, Chrousos G, Tzortzatou-Stathopoulou F. Early indicators of dysmetabolic syndrome in young survivors of acute lymphoblastic leukemia in childhood as a target for preventing disease. J Pediatr Hematol Oncol. 2007;29(5):309–14. doi:10.1097/MPH.0b013e318059c249.CrossRefPubMed

68.

Gunn HM, Emilsson H, Gabriel M, Maguire AM, Steinbeck KS. Metabolic health in childhood cancer survivors: a longitudinal study in a long-term follow-up clinic. J Adolesc Young Adult Oncol. 2015. doi:10.1089/jayao.2015.0036.

Medicine Matters Oncology

Abstract